البلد: أيرلندا
اللغة: الإنجليزية
المصدر: HPRA (Health Products Regulatory Authority)
VENLAFAXINE HYDROCHLORIDE
PCO Manufacturing
37.5mg Milligram
Tablets
0000-00-00
PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Efexor 37.5mg Tablets. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 37.5 mg of venlafaxine (as hydrochloride). Excipients: Lactose For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Tablet. _Product imported from Greece:_ Peach coloured, shield shaped tablet impressed with the tablet strength ‘37.5’ and embossed with a ‘W’ on one face, and plain on the other. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Efexor is indicated for the treatment of depressive illness in both hospitalised patients and outpatients, including depression accompanied by anxiety. Following an initial response Efexor is indicated for the prevention of relapses of the initial episode of depression or for the prevention of the recurrence of new episodes. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION _Adults:_ The usual recommended dose is 75mg per day given in two divided doses (37.5mg twice daily). If, after several weeks, further clinical improvement is required, the dose may be increased to 150mg per day given in two divided doses (75mg twice daily). If, in the judgement of the physician, a higher dose is required, for example in more severely depressed or hospitalised patients, a starting dose of 150mg per day may be given in two divided doses (75mg twice daily). The daily dose may then be increased by up to 75mg every two or three days until the desired response is achieved. The maximum recommended dose is 375mg per day. The dose should then be gradually reduced to the usual dosage, consistent with patient response and tolerance. Usually, the dosage for prevention of relapse or for prevention of recurrence of a new episode is similar to that used during the index episod اقرأ الوثيقة كاملة